000305417 001__ 305417
000305417 005__ 20251020115507.0
000305417 0247_ $$2doi$$a10.1172/JCI187627
000305417 0247_ $$2pmid$$apmid:41100815
000305417 0247_ $$2ISSN$$a0021-9738
000305417 0247_ $$2ISSN$$a1558-8238
000305417 037__ $$aDKFZ-2025-02146
000305417 041__ $$aEnglish
000305417 082__ $$a610
000305417 1001_ $$0P:(DE-He78)0921630050b802a96db645029b1a982b$$aFunk, Cornelius$$b0$$eFirst author$$udkfz
000305417 245__ $$aHigh 4E-BP-1 expression associates with chromosome 8 gain and CDK4/6 sensitivity in Ewing Sarcoma.
000305417 260__ $$aAnn Arbor, Mich.$$bASCJ$$c2025
000305417 3367_ $$2DRIVER$$aarticle
000305417 3367_ $$2DataCite$$aOutput Types/Journal article
000305417 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1760949612_1189493
000305417 3367_ $$2BibTeX$$aARTICLE
000305417 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000305417 3367_ $$00$$2EndNote$$aJournal Article
000305417 500__ $$a#EA:B410#LA:B410# / epub
000305417 520__ $$aChromosome 8 (chr8) gains are common in cancer, but their contribution to tumor heterogeneity is largely unexplored. Ewing sarcoma (EwS) is defined by FET::ETS fusions with few other recurrent mutations to explain clinical diversity. In EwS, chr8 gains are the second most frequent alteration, making it an ideal model to study their relevance in an otherwise silent genomic context. We report that chr8 gain-driven expression patterns correlate with poor overall survival of EwS patients. This effect is mainly mediated by increased expression of the translation initiation factor binding protein 4E-BP1, encoded by EIF4EBP1 on chr8. Among all chr8-encoded genes, EIF4EBP1 expression showed the strongest association with poor survival and correlated with chr8 gains in EwS tumors. Similar findings emerged across multiple TCGA cancer entities. Multi-omics profiling revealed that 4E-BP1 orchestrates a pro-proliferative proteomic network. Silencing 4E-BP1 reduced proliferation, clonogenicity, spheroidal growth in vitro, and tumor growth in vivo. Drug screens demonstrated that high 4E-BP1 expression sensitizes EwS to pharmacological CDK4/6-inhibition. Chr8 gains and elevated 4E-BP1 emerge as prognostic biomarkers in EwS, with poor outcomes driven by 4E-BP1-mediated pro-proliferative networks that sensitize tumors to CDK4/6 inhibitors. Testing for chr8 gains may enhance risk stratification and therapy in EwS and other cancers.
000305417 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000305417 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000305417 650_7 $$2Other$$aCancer
000305417 650_7 $$2Other$$aGenetic variation
000305417 650_7 $$2Other$$aGenetics
000305417 650_7 $$2Other$$aMouse models
000305417 650_7 $$2Other$$aOncology
000305417 7001_ $$0P:(DE-He78)9b3d0cef2b1553fc9d2c5f24d91c12e1$$aEhlers, Anna$$b1$$eFirst author$$udkfz
000305417 7001_ $$aOrth, Martin F$$b2
000305417 7001_ $$0P:(DE-He78)c51d9cafe6d7e6e3c91b299ed8014858$$aAljakouch, Karim$$b3$$udkfz
000305417 7001_ $$0P:(DE-He78)b37e68255201ee3a776f69fd2462a099$$aLi, Jing$$b4$$udkfz
000305417 7001_ $$0P:(DE-HGF)0$$aHoelting, Tilman Lb$$b5
000305417 7001_ $$0P:(DE-He78)18218139eec55d83cf82679934e5cd75$$aWill, Rainer$$b6$$udkfz
000305417 7001_ $$0P:(DE-He78)824510670ec489266e6e294c4f8b0e6c$$aGeyer, Florian H$$b7$$udkfz
000305417 7001_ $$0P:(DE-He78)4f8b6ddd5c9a7b08d3d59c5f7e275cf9$$aCeranski, A Katharina$$b8$$udkfz
000305417 7001_ $$aWillis, Franziska$$b9
000305417 7001_ $$0P:(DE-He78)a46733606e787aeb59c33d2a642d02d7$$aVinca, Endrit$$b10
000305417 7001_ $$0P:(DE-He78)c25b54b0c834093d1f884d2615e305d6$$aOhmura, Shunya$$b11$$udkfz
000305417 7001_ $$0P:(DE-He78)3c021852cf94cb29825e65baa82ed54b$$aImle, Roland$$b12$$udkfz
000305417 7001_ $$0P:(DE-He78)a804dfb61b29a00e81bb457c172efce3$$aSiebenlist, Jana$$b13
000305417 7001_ $$0P:(DE-He78)f55d074b17fca49f1c411dfae4d30a93$$aYershova, Angelina$$b14$$udkfz
000305417 7001_ $$aKnott, Maximilian Ml$$b15
000305417 7001_ $$0P:(DE-He78)ec64d75fe6aad968b3981bc1c1529f72$$aZahnow, Felina$$b16$$udkfz
000305417 7001_ $$aSastre, Ana$$b17
000305417 7001_ $$aAlonso, Javier$$b18
000305417 7001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b19$$udkfz
000305417 7001_ $$aPeterziel, Heike$$b20
000305417 7001_ $$aLoboda, Anna$$b21
000305417 7001_ $$aSchneider, Martin$$b22
000305417 7001_ $$0P:(DE-He78)990de6ec6c2f0a40b17ed75162ca19e8$$aBanito, Ana$$b23$$udkfz
000305417 7001_ $$aLeprivier, Gabriel$$b24
000305417 7001_ $$aHartmann, Wolfgang$$b25
000305417 7001_ $$aDirksen, Uta$$b26
000305417 7001_ $$0P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aWitt, Olaf$$b27$$udkfz
000305417 7001_ $$0P:(DE-He78)908367a659dea9e28dac34592b3c46e5$$aOehme, Ina$$b28$$udkfz
000305417 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan M$$b29$$udkfz
000305417 7001_ $$0P:(DE-HGF)0$$aRomero-Pérez, Laura$$b30
000305417 7001_ $$0P:(DE-He78)939d5891259c638c1ab053b1456a578c$$aKrijgsveld, Jeroen$$b31$$udkfz
000305417 7001_ $$0P:(DE-HGF)0$$aCidre-Aranaz, Florencia$$b32
000305417 7001_ $$0P:(DE-He78)7a590ab95c6f7ba52880452da78ecd6c$$aGrünewald, Thomas$$b33$$eLast author$$udkfz
000305417 7001_ $$0P:(DE-He78)476ba475ebb0d48ae4ec27f03d836a41$$aMusa, Julian$$b34$$eLast author$$udkfz
000305417 773__ $$0PERI:(DE-600)2018375-6$$a10.1172/JCI187627$$pnn$$tThe journal of clinical investigation$$vnn$$x0021-9738$$y2025
000305417 909CO $$ooai:inrepo02.dkfz.de:305417$$pVDB
000305417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0921630050b802a96db645029b1a982b$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000305417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9b3d0cef2b1553fc9d2c5f24d91c12e1$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000305417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c51d9cafe6d7e6e3c91b299ed8014858$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000305417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b37e68255201ee3a776f69fd2462a099$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000305417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000305417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)18218139eec55d83cf82679934e5cd75$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000305417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)824510670ec489266e6e294c4f8b0e6c$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000305417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4f8b6ddd5c9a7b08d3d59c5f7e275cf9$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000305417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a46733606e787aeb59c33d2a642d02d7$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000305417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c25b54b0c834093d1f884d2615e305d6$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000305417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3c021852cf94cb29825e65baa82ed54b$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000305417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a804dfb61b29a00e81bb457c172efce3$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000305417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f55d074b17fca49f1c411dfae4d30a93$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000305417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ec64d75fe6aad968b3981bc1c1529f72$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000305417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000305417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)990de6ec6c2f0a40b17ed75162ca19e8$$aDeutsches Krebsforschungszentrum$$b23$$kDKFZ
000305417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aDeutsches Krebsforschungszentrum$$b27$$kDKFZ
000305417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)908367a659dea9e28dac34592b3c46e5$$aDeutsches Krebsforschungszentrum$$b28$$kDKFZ
000305417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b29$$kDKFZ
000305417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b30$$kDKFZ
000305417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)939d5891259c638c1ab053b1456a578c$$aDeutsches Krebsforschungszentrum$$b31$$kDKFZ
000305417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b32$$kDKFZ
000305417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7a590ab95c6f7ba52880452da78ecd6c$$aDeutsches Krebsforschungszentrum$$b33$$kDKFZ
000305417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)476ba475ebb0d48ae4ec27f03d836a41$$aDeutsches Krebsforschungszentrum$$b34$$kDKFZ
000305417 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000305417 9141_ $$y2025
000305417 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CLIN INVEST : 2022$$d2024-12-27
000305417 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-27
000305417 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-27
000305417 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-02-16T10:37:49Z
000305417 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-02-16T10:37:49Z
000305417 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review$$d2024-02-16T10:37:49Z
000305417 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2024-02-16T10:37:49Z
000305417 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-27
000305417 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-27
000305417 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-27
000305417 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-27
000305417 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-27
000305417 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-27
000305417 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-27
000305417 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-27
000305417 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-27
000305417 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bJ CLIN INVEST : 2022$$d2024-12-27
000305417 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-27
000305417 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-27
000305417 9202_ $$0I:(DE-He78)B410-20160331$$kB410$$lTranslationale Pädiatrische Sarkomforschung$$x0
000305417 9201_ $$0I:(DE-He78)B410-20160331$$kB410$$lTranslationale Pädiatrische Sarkomforschung$$x0
000305417 9201_ $$0I:(DE-He78)B230-20160331$$kB230$$lB230 Proteomik von Stammzellen und Krebs$$x1
000305417 9201_ $$0I:(DE-He78)W111-20160331$$kW111$$lZelluläre Tools$$x2
000305417 9201_ $$0I:(DE-He78)B380-20160331$$kB380$$lNWG Weichteilsarkome$$x3
000305417 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x4
000305417 9201_ $$0I:(DE-He78)B310-20160331$$kB310$$lKKE Pädiatrische Onkologie$$x5
000305417 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x6
000305417 9200_ $$0I:(DE-He78)B410-20160331$$kB410$$lTranslationale Pädiatrische Sarkomforschung$$x0
000305417 980__ $$ajournal
000305417 980__ $$aVDB
000305417 980__ $$aI:(DE-He78)B410-20160331
000305417 980__ $$aI:(DE-He78)B230-20160331
000305417 980__ $$aI:(DE-He78)W111-20160331
000305417 980__ $$aI:(DE-He78)B380-20160331
000305417 980__ $$aI:(DE-He78)B300-20160331
000305417 980__ $$aI:(DE-He78)B310-20160331
000305417 980__ $$aI:(DE-He78)B062-20160331
000305417 980__ $$aUNRESTRICTED